A novel pathway in NSCLC cells: miR‑191, targeting NFIA, is induced by chronic hypoxia, and promotes cell proliferation and migration

Zhao,Jia; Qiao,Cheng‑Rui; Ding,Zheng; Sheng,Yin‑Liang; Li,Xiang‑Nan; Yang,Yang; Zhu,Deng‑Yan; Zhang,Chun‑Yang; Liu,Dong‑Lei; Wu,Kai; Zhao,Song

doi:10.3892/mmr.2017.6100

A novel pathway in NSCLC cells: miR‑191, targeting NFIA, is induced by chronic hypoxia, and promotes cell proliferation and migration

Authors:
- Jia Zhao
- Cheng‑Rui Qiao
- Zheng Ding
- Yin‑Liang Sheng
- Xiang‑Nan Li
- Yang Yang
- Deng‑Yan Zhu
- Chun‑Yang Zhang
- Dong‑Lei Liu
- Kai Wu
- Song Zhao
View Affiliations

Affiliations: Department of Thoracic Surgery, First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
Published online on: January 4, 2017 https://doi.org/10.3892/mmr.2017.6100
Pages: 1319-1325

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRs) have emerged as being important in cancer biology. miR‑191 is a conserved miRNA, which has been investigated in detail and is reported to be induced by hypoxia-inducible factor (HIF)‑1α and has an contributory action in the progression of breast, hepatic and pancreatic cancer. However, the effects of miR‑191 in the progression of lung cancer are a subject of debate. In the present study, it was found that the expression of miR-191 was significantly upregulated in non‑small cell lung cancer (NSCLC) cells in patients in vivo. However, the levels of miR‑191 remained unchanged in SK‑MES‑1, A549 and NCI‑H460 NSCLC cell lines, compared with the level in the normal HBE lung cell line, however, the levels were markedly upregulated in these NSCLC cell lines under conditions of chronic hypoxia. Subsequently, an miR‑191 mimic was transfected into the NSCLC cell lines to examine its effect on the progression of the NSCLC cells in vitro. The data obtained using MTT and Cell counting kit‑8 assays revealed that miR‑191 had no effect on the proliferation of the cells under normal condition, however, their proliferation was promoted under mild hypoxic conditions. In addition, the results of a Transwell migration assay showed that miR‑191 had a promoting effect on NSCLC cell migration under the conditions of chronic hypoxia. Furthermore, the TargetScan bioinformatics server and 3'-untranslated region luciferase reporter assay indicated that the transcription factor, nuclear factor 1α (NFIA) was a target of miR‑191. Subsequent western blot analysis showed that, in chronic‑hypoxia, the protein levels of NFIA and the tumor suppressor, CCAAT-enhancer-binding protein α, were sharply reduced in A549 cells. In conclusion, miR‑191 was induced by chronic hypoxia and promoted the proliferation and migration of NSCLC cells under chronic hypoxic conditions. This promotion may be associated with its targeting of NFIA. The present findings may provide a potential molecular target for the therapeutic treatment of NSCLC.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Zhang S, Zhao P, Zeng H and Zou X: Report of cancer incidence and mortality in China, 2010. Ann Transl Med. 2:612014.PubMed/NCBI
3	Chen WQ, Zheng RS, Zhang SW, Zeng HM and Zou XN: The incidences and mortalities of major cancers in China, 2010. Chin J Cancer. 33:402–405. 2014.PubMed/NCBI
4	McKee MD, Bondarenko I, Guclu SZ, et al: Veliparib (ABT-888) or placebo combined with carboplatin and paclitaxel in patients with previously untreated advanced/metastatic squamous (Sq) non-small cell lung cancer (NSCLC): A randomized phase 3 trial. ASCO Annual Meeting Proceedings. pp. TPS8107Chicago, IL: 2015
5	Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG and Shepherd FA: Non-small-cell lung cancer. Lancet. 378:1727–1740. 2011. View Article : Google Scholar : PubMed/NCBI
6	Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, et al: Non-small cell lung cancer. J Natl Compr Canc Netw. 10:1236–1271. 2012.PubMed/NCBI
7	Li H, Chen SJ, Chen YF, Meng QC, Durand J, Oparil S and Elton TS: Enhanced endothelin-1 and endothelin receptor gene expression in chronic hypoxia. J Appl Physiol (1985). 77:1451–1459. 1994.PubMed/NCBI
8	Smith TG, Robbins PA and Ratcliffe PJ: The human side of hypoxia-inducible factor. Br J Haematol. 141:325–334. 2008. View Article : Google Scholar : PubMed/NCBI
9	Parvin A, Pranap R, Shalini U, Devendran A, Baker JE and Dhanasekaran A: Erythropoietin protects cardiomyocytes from cell death during hypoxia/reperfusion injury through activation of survival signaling pathways. PLoS One. 9:e1074532014. View Article : Google Scholar : PubMed/NCBI
10	Huang W, Liu X, Cao J, Meng F, Li M, Chen B and Zhang J: miR-134 regulates ischemia/reperfusion injury-induced neuronal cell death by regulating CREB signaling. J Mol Neurosci. 55:821–829. 2015. View Article : Google Scholar : PubMed/NCBI
11	Simon MC: Abstract IA13: A hypoxic microenvironment influences pancreatic cancer progression. Cancer Res. 75:IA13. 2015. View Article : Google Scholar
12	Shay JE, Imtiyaz HZ, Sivanand S, Durham AC, Skuli N, Hsu S, Mucaj V, Eisinger-Mathason TS, Krock BL, Giannoukos DN and Simon MC: Inhibition of hypoxia-inducible factors limits tumor progression in a mouse model of colorectal cancer. Carcinogenesis. 35:1067–1077. 2014. View Article : Google Scholar : PubMed/NCBI
13	Amelio I and Melino G: The p53 family and the hypoxia-inducible factors (HIFs): Determinants of cancer progression. Trends Biochem Sci. 40:425–434. 2015. View Article : Google Scholar : PubMed/NCBI
14	Zhang L, Flygare J, Wong P, Lim B and Lodish HF: miR-191 regulates mouse erythroblast enucleation by down-regulating Riok3 and Mxi1. Genes Dev. 25:119–124. 2011. View Article : Google Scholar : PubMed/NCBI
15	Nagpal N and Kulshreshtha R: miR-191: An emerging player in disease biology. Front Genet. 5:992014. View Article : Google Scholar : PubMed/NCBI
16	Di Leva G and Croce CM: miRNA profiling of cancer. Curr Opin Genet Dev. 23:3–11. 2013. View Article : Google Scholar : PubMed/NCBI
17	Liu R, Chen X, Du Y, Yao W, Shen L, Wang C, Hu Z, Zhuang R, Ning G, Zhang C, et al: Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem. 58:610–618. 2012. View Article : Google Scholar : PubMed/NCBI
18	Collins AL, Wojcik S, Liu J, Frankel WL, Alder H, Yu L, Schmittgen TD, Croce CM and Bloomston M: A differential microRNA profile distinguishes cholangiocarcinoma from pancreatic adenocarcinoma. Ann Surg Oncol. 21:133–138. 2014. View Article : Google Scholar : PubMed/NCBI
19	Nagpal N, Ahmad HM, Chameettachal S, Sundar D, Ghosh S and Kulshreshtha R: HIF-inducible miR-191 promotes migration in breast cancer through complex regulation of TGFβ-signaling in hypoxic microenvironment. Sci Rep. 5:96502015. View Article : Google Scholar : PubMed/NCBI
20	He Y, Cui Y, Wang W, Gu J, Guo S, Ma K and Luo X: Hypomethylation of the hsa-miR-191 locus causes high expression of hsa-mir-191 and promotes the epithelial-to-mesenchymal transition in hepatocellular carcinoma. Neoplasia. 13:841–853. 2011. View Article : Google Scholar : PubMed/NCBI
21	Song Z, Ren H, Gao S, Zhao X, Zhang H and Hao J: The clinical significance and regulation mechanism of hypoxia-inducible factor-1 and miR-191 expression in pancreatic cancer. Tumor Biol. 35:11319–11328. 2014. View Article : Google Scholar
22	Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006. View Article : Google Scholar : PubMed/NCBI
23	Patnaik SK, Kannisto E and Yendamuri S: Overexpression of microRNA miR-30a or miR-191 in A549 lung cancer or BEAS-2B normal lung cell lines does not alter phenotype. PloS One. 5:e92192010. View Article : Google Scholar : PubMed/NCBI
24	Zhou W, Wang G, Zhao X, Xiong F, Zhou S, Peng J, Cheng Y, Xu S and Xu X: A multiplex qPCR gene dosage assay for rapid genotyping and large-scale population screening for deletional α-thalassemia. J Mol Diagn. 15:642–651. 2013. View Article : Google Scholar : PubMed/NCBI
25	Markou A, Sourvinou I, Vorkas PA, Yousef GM and Lianidou E: Clinical evaluation of microRNA expression profiling in non small cell lung cancer. Lung Cancer. 81:388–396. 2013. View Article : Google Scholar : PubMed/NCBI
26	Nadal E, Chen G, Chang AC, Lin J, Reddy R, Orringer MB and Beer DG: Ratio of miR-146b/miR-191 in serum predicts prognosis in surgically resected lung squamous cell carcinomas. Cancer Res. 72:41472012. View Article : Google Scholar
27	Puisségur MP, Mazure NM, Bertero T, Pradelli L, Grosso S, Robbe-Sermesant K, Maurin T, Lebrigand K, Cardinaud B, Hofman V, et al: miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ. 18:465–478. 2011. View Article : Google Scholar : PubMed/NCBI
28	Elson DA, Ryan HE, Snow JW, Johnson R and Arbeit JM: Coordinate up-regulation of hypoxia inducible factor (HIF)-1alpha and HIF-1 target genes during multi-stage epidermal carcinogenesis and wound healing. Cancer Res. 60:6189–6195. 2000.PubMed/NCBI
29	Wang N, Dong CR, Jiang R, Tang C, Yang L, Jiang QF, Chen GG and Liu ZM: Overexpression of HIF-1α, metallothionein and SLUG is associated with high TNM stage and lymph node metastasis in papillary thyroid carcinoma. Int J Clin Exp Pathol. 7:322–330. 2013.PubMed/NCBI
30	Wu Y, Mao F, Zuo X, Moussalli MJ, Elias E, Xu W and Shureiqi I: 15-LOX-1 suppression of hypoxia-induced metastatic phenotype and HIF-1α expression in human colon cancer cells. Cancer Med. 3:472–484. 2014. View Article : Google Scholar : PubMed/NCBI
31	Liu C, Duan P, Li B, Huang C, Jing Y and Yan W: miR-29a activates Hes1 by targeting Nfia in esophageal carcinoma cell line TE-1. Oncol Lett. 9:96–102. 2015.PubMed/NCBI
32	Lee JS, Xiao J, Patel P, Schade J, Wang J, Deneen B, Erdreich-Epstein A and Song HR: A novel tumor-promoting role for nuclear factor IA in glioblastomas is mediated through negative regulation of p53, p21, and PAI1. Neuro Oncol. 16:191–203. 2014. View Article : Google Scholar : PubMed/NCBI
33	Song HR, Gonzalez-Gomez I, Suh GS, Commins DL, Sposto R, Gilles FH, Deneen B and Erdreich-Epstein A: Nuclear factor IA is expressed in astrocytomas and is associated with improved survival. Neuro Oncol. 12:122–132. 2010. View Article : Google Scholar : PubMed/NCBI